Risk factors associated with tumor upstaging in melanomas treated with Mohs micrographic surgery with melanocytic immunohistochemistry

Mohs micrographic surgery with melanocytic immunohistochemistry (MMS-I) is increasingly utilized for special site melanoma treatment. Yet, frequency and risk factors associated with upstaging of all-stage cutaneous melanomas treated with MMS-I remain undefined. Determine upstaging frequency and fact...

Full description

Saved in:
Bibliographic Details
Published in:JAAD international 2024-09, Vol.16, p.3-8
Main Authors: Trischman, Thomas, Bangalore Kumar, Anagha, Asamoah, Eucabeth M., Todd, Austin, Vidal, Nahid Y., Demer, Addison M.
Format: Article
Language:English
Subjects:
dermatologic surgery
lentigo maligna
melanoma
melanoma in situ
melanoma upstaging
melanoma upstaging with Mohs
Mohs for melanoma
Mohs micrographic surgery
Mohs with immunohistochemistry
Original
upstaging
wide local excision
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mohs micrographic surgery with melanocytic immunohistochemistry (MMS-I) is increasingly utilized for special site melanoma treatment. Yet, frequency and risk factors associated with upstaging of all-stage cutaneous melanomas treated with MMS-I remain undefined. Determine upstaging frequency and factors associated with tumor upstaging for all-stage melanomas treated with MMS-I. In this retrospective, single-center case series, all cases of invasive and in situ melanoma treated with MMS-I between 2008 and 2018 were reviewed. Patient and tumor characteristics were recorded and compared between tumors that were and were not upstaged from their initial T stage. Of the 962 melanoma MMS-I cases identified, 44 (4.6%) were upstaged, including 5.6% of in situ and 2.5% of invasive tumors. Risk factors for upstaging included lack of excisional intent at the time of initial biopsy (P 
ISSN:2666-3287
2666-3287
DOI:10.1016/j.jdin.2024.02.006